"I am delighted to welcome Anil to the Nurix board as we enter this important stage in the company's development and execute ...

Furthest ahead in the pipeline is tolebrutinib, developed by Paris-based Sanofi to potentially treat SPMS, PPMS and relapsing forms of MS. The investigational agent is an oral central nervous system ...

Oditrasertib, which blocks the inflammatory RIPK1 protein, earlier this year also failed a Phase II trial in amyotrophic ...

Dr Jiwon Oh reflects on her discussions with patients on promising results reported at ECTRIMS in relapsing and progressive MS.

Highlights in relapsing-remitting multiple sclerosis from ECTRIMS 2024 include treatment for pediatric-onset MS, safety of frexalimab, pregnancy-related considerations, and efficacy of tolebrutinib.

PRESS RELEASEAB SCIENCE PRESENTS ITS FINANCIAL RESULTS FOR THE FIRST HALF OF 2024 AND THE KEY EVENTS OF THE PERIODClinical ...

In a phase 3 trial, tolebrutinib has a significant effect on slowing disability progression in some patients with multiple sclerosis..

These statements include, but are not limited to, statements regarding the combination potential for MALT1 and BTK inhibitors in models of B-cell malignancies, PD biomarkers related to LSD1 ...

Poster Presentations Title: Combining next-generation BTK and MALT1 inhibitors to enhance efficacy and therapeutic utility in B-cell malignancies Session Title: Combination therapies Catalog ...

“As our precision-designed LSD1 and MALT1 inhibitors continue to progress towards the clinic, we are excited to share new preclinical data from both programmes,” said David Hallett, Ph.D., interim ...